Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celltrion has received approval from the FDA to serve as a contract manufacturer to produce Orencia, a novel biologic agent for the treatment of rheumatoid arthritis, developed by Bristol-Myers Squibb.
Subscribe to our email newsletter
The supplemental biological license application (sBLA) was submitted by Bristol-Myers Squibb Company to meet expected long-term demand for Orencia.
Jung-Jin Seo, chairman and CEO of Celltrion, said: “Achieving sBLA approval from the FDA to manufacture Orencia is an important milestone that reinforces our vision to become a fully integrated global biotechnology company.”